| | Diabetes | | | Taking Control of Glycemia in Type 2 Diabetes Patients with Cardiovascular Risk
Overview
More than 20 million people in the United States are affected by diabetes, with 1.5 million new cases appearing each year. Of this population, nearly 65% will die from heart disease or stroke, a rate that is 4-times higher than in the non-diabetic population. Individualized and early glycemic control is critical in the prevention and management of diabetes and in reducing cardiovascular risk. This activity will expose attendees to the relationship between insulin resistance, type 2 diabetes, and the resulting cardiovascular risk in an effort to uncover effective treatment strategies and patient-based therapeutic options.
Objectives
Utilize appropriate glucose-lowering agents to reduce A1C to * 7.0%
Minimize adverse events and cardiovascular risk associated with glycemic therapy by employing appropriate glucose, blood pressure, and serum cholesterol agents
Faculty
Mark Stolar, MD
Associate Professor of Clinical Medicine
Northwestern University
The Feinberg School of Medicine
Chicago, IL
Natasa Janicic-Kahric, MD, PhD
Assistant Professor of Medicine
Division of Endocrinology and Metabolism
Georgetown University Hospital
Washington, DC
| | | IBS | | | Success in IBS: Deconstructing the Barriers to Optimal Management in Irritable Bowel Syndrome
Overview
Irritable bowel syndrome (IBS) is a highly misunderstood functional bowel disorder that is underreported and underdiagnosed. Because IBS can be challenging to diagnose and manage, it is important that clinicians stay up-to-date on current developments of diagnostic and treatment options in IBS.
Objectives
Recognize the symptoms of IBS and employ ACG guidelines and Rome III criteria to make a symptom-based diagnosis of IBS
Implement a patient-centered and evidence-based approach to the treatment of IBS, taking patientsÕ treatment goals into consideration as well as the efficacy, safety, and mechanisms of action of available treatment options
Faculty
Suzanne Rose, MD, MSEd
Professor of Medical Education and Medicine, Division of Gastroenterology
Associate Dean for Academic and Student Affairs
Associate Dean for Continuing Medical Education
Mount Sinai School of Medicine
New York, NY
Jennifer A. Christie, MD
Assistant Professor
Director of Gastrointestinal Motility
Emory University School of Medicine
Atlanta, GA
| | | Rhinitis | | | Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Healthcare Professional
Overview
Allergic rhinitis (AR) is the most common allergic condition in the US, affecting nearly 40 million people. Although AR is associated with significant comorbidities, current therapies have proven only modestly successful. Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional will provide primary care physicians with practical, evidence-based solutions to the challenges of managing AR, with particular emphasis on finding effective treatments and ensuring patient compliance. Two nationally recognized allergy/immunology experts will lead each 75-minute presentation with 60 minutes of didactic lectures and case history presentation, and a 15-minute question-and-answer session. Interactive discussion and a dynamic audience response system will also be integrated into the session.
Objectives
Describe key clinical characteristics of allergic rhinitis, its associated comorbidities, and its impact on patient health and quality of life
Identify barriers to treatment success of allergic rhinitis (treatment-related, physician-related, and patient-related barriers) and adequate control of symptoms, and devise strategies for overcoming those barriers
Faculty
Alexander N. Greiner, MD
University of CA, San Diego, School of Medicine
San Diego, CA
Myron Zitt, MD
| | | Menopause | | | Dialogues in Menopause Management: Facilitating Patient Counseling about Hormone Therapy
Overview
Healthcare providers and patients alike receive confusing, and even seemingly conflicting, data about the benefit-risk ratio associated with menopausal hormone therapy (HT). In this program, the faculty will present risk concepts in general as well as the most current evidence regarding HT risks and benefitsÑ and how to clearly explain this evidence to their diverse patient population for which HT is considered. The goal of the program is to avoid misperception about HT riskÑand, therefore, faulty decision making.
Objectives
Define absolute risk, relative risk, and clinically significant risk of adverse events and exposure history in meaningful terms as it relates to hormone therapy
Identify clinical guidelines and evidence-based approaches for counseling a diverse patient population on the potential benefits and risks of hormone therapy
Faculty
Bruce Ettinger, MD
Emeritus Clinical Professor Medicine
University of California, San Francisco
San Francisco, CA
Adjunct Investigator
Division of Research
Kaiser Permanente Medical Care Program
Oakland, CA
Cynthia A. Stuenkel, MD
Clinical Professor of Medicine
University of California, San Diego
La Jolla, CA
| | | Hypertension | | | Management of the Moderate-to-Severe Hypertensive: Individualizing Treatment to Maximize Outcomes
Overview
This program will underscore the need for early, aggressive, combination BP treatment in order to reach JNC 7 goals, in light of the effect hypertension and diabetes has on the pathogenesis of hypertensive renal damage. It will explain the mechanisms of action of the various antihypertensive drug classes and how clinicians can use this understanding when selecting a drug regimen. Based on recent and ongoing trials, the safest and most efficacious drug combinations will be discussed.
Objectives
Develop appropriate combination therapy regimens individualized to each diabetic hypertensive patientÕs established risk and comorbid conditions
Demonstrate an understanding of the role of renin-aniotensin-aldosterone system blockers in the treatment of hypertension, the prevention of new onset diabetes, and the prevention of progression in diabetic nephropathy by selecting the most appropriate treatment regimen for diabetic hypertensive patients
Faculty
John R. Steinberg, MD
Volunteer Faculty
University of Maryland School of Medicine
Baltimore, MD
Domenic A. Sica, MD
Professor of Medicine
Medical College of Virginia
Virginia Commonwealth University
Richmond, VA
| | | Dyslipidemia | | | The Moving LDL Target: Getting Your Patients to Goal
Overview
The current use of lipid lowering therapy in clinical practice has fallen short of the recommendations of national guidelines. Clearly, not an easy venture when treating patients with dyslipidemia, many with multiple risk factors and many with resulting coronary events that may be preventable if patients were treated aggressively to meet the NCEP-ATP lll goals. This presentation will address the clinical challenges of goal attainment (lack of compliance, aggressive treatment by clinicians, not leaving patients 15 points from goals), and provide clinicians with the pathways and knowledge to help attain their patients to goal.
Objectives
Describe at least two challenges in treating dyslipidemia to NCEP-ATP III goals, implement strategies that will help to assess CHD risk accurately, and get patients to targeted goals
Identify patients at increased risk for cardiovascular events and develop a treatment plan with at least 2 lipid lowering strategies, including the use of multiple therapies, which will help these patients achieve guideline-based targets taking into consideration current lifestyle and pharmacologic treatment options available thus reducing overall cardiovascular risk
Faculty
Emma Meagher, MD
Associate Professor, Medicine and Pharmacology Executive Chair
University of Pennsylvania, School of Medicine
Philadelphia, PA
Albert Levy, MD, FAAFP
Assistant Clinical Professor Medicine
Mount Sinai School of Medicine
New York, NY
| | | Osteoporosis | | | Appropriate Identification and Treatment of Non-vertebral Fractures
Overview
This program is designed to provide primary care providers with information about the state of the science and evidence-based strategies for the accurate identification and comprehensive treatment of osteoporosis.
Objectives
Identify appropriate diagnostic tools & procedures that can be employed for early diagnosis of osteoporosis
Evaluate the treatment strategies, including methods of administration and MOAs of various antiresorptive agents that are currently available to prevent fractures and treat osteoporosis
Faculty
John Bilezikian, MD
Abby Abelson, MD
| | | HPV | | | Reducing the Burden of HPV-Related Diseases: Cervical Cancer and Beyond
Overview
Human papillomavirus (HPV) is the most common newly acquired sexually transmitted infection in the United States. It is a necessary cause of cervical cancer and genital warts, and is associated with other anogenital and head and neck cancers, and recurrent respiratory papillomatosis. Prevention of HPV infection through prophylactic vaccination provides a safe and effective option to reduce the health burden associated with HPV-related diseases. Two vaccines have been developed: a quadrivalent HPV (6, 11, 16, 18) vaccine, approved by the US Food and Drug Administration (FDA), and a bivalent HPV (16, 18) vaccine, currently under FDA review. Both vaccines have demonstrated lasting efficacy against HPV-associated cervical disease and are generally well tolerated. This program will review the health consequences of HPV infection; provide an update on the safety and efficacy of HPV vaccines, including recent data on efficacy in mid-adult women, duration of protection, and cross-protection against nonvaccine HPV types; and evaluate the benefits of widespread HPV vaccination in preventing HPV-related diseases.
Objectives
Describe the epidemiology, natural history and consequences of HPV infection
Evaluate the anticipated benefits of widespread HPV vaccination in preventing cervical and anogenital cancers, genital warts, and other HPV-related diseases
Faculty
Edward John Mayeaux, Jr., MD
Professor of Family Medicine, Obstetrics & Gynecology
Louisiana State University Health Sciences Center
Shreveport, LA
Martin C. Mahoney, MD, PhD
Director, Cancer Prevention & Detection Center
Roswell Park Cancer Institute
Associate Professor of Family Medicine
State University of New York at Buffalo
Buffalo, NY
| | | Zoster Virus | | | Preventing Herpes Zoster and Postherpetic Neuralgia: Are Your Patients Adequately Protected?
Overview
An estimated 1 million cases of herpes zoster (shingles) occur annually in the United States. The incidence and severity of herpes zoster increase with advancing age to produce substantial negative effects on quality of life, activities of daily living, neuropsychological functioning, and social status, resulting in significant morbidity in older adults. While antiviral therapy reduces the incidence and severity of herpes zoster, it does not reliably prevent postherpetic neuralgia (PHN), the most common and debilitating clinical sequela of herpes zoster. Herpes zoster vaccination has been demonstrated to reduce the incidence of the disease and its complications. Clinical trial data have demonstrated significant reductions in the incidence of herpes zoster and PHN, as well as overall reductions in the burden of disease.
Objectives
Review the benefits and limitations of current treatment options for herpes zoster and postherpetic neuralgia (PHN)
Evaluate clinical trial results of the herpes zoster vaccine and discuss current recommendations of the Advisory Committee on Immunization Practices for the prevention of herpes zoster
Faculty
Katherine E. Galluzzi, DO, FACOFP
Professor and Chairperson
Department of Geriatrics
Philadelphia College of Osteopathic Medicine
Philadelphia, PA
M. Susan Burke, MD, FACP
Clinical Assistant Professor of Medicine
Thomas Jefferson University
Philadelphia, Pennsylvania
Director, Internal Medicine Clinical Care Center
Lankenau Hospital
Wynnewood, PA
| | | Mood Disorders | | | Managing Mood and Anxiety Disorders in Primary Care Practice: A Focus on Complex and Difficult-to-Treat Patients
Overview
Bipolar disorder (BD) and major depressive disorder (MDD) are two of the most prevalent psychiatric disorders in adults. These conditions are associated with overlapping disorders of mood including anxiety and depression; differentiating the two disorders can be difficult and can lead to misdiagnosis and mismanagement. This activity will focus on practical approaches to the diagnosis and management of the Òdifficult-to-treatÓ patient presenting with depression associated with MDD and BD.
Objectives
Recognize overlapping symptomatology and comorbid psychiatric disorders that can complicate the differential diagnosis of depression
Design and implement practical strategies to diagnosis and manage the difficult-to-treat patient with depression associated with major depressive disorder and bipolar disorder
Faculty
J. Sloan Manning, MD
Adjunct Associate Professor
University of North Carolina - Chapel Hill
Co-Director, Mood Disorders Clinic
Moses Cone Family Practice Residency
Greensboro, NC
Robert M.A. Hirschfeld, MD
Titus H. Harris Chair
Harry K. Davis Professor
Professor and Chairperson
Department of Psychiatry and Behavioral Sciences
University of Texas Medical Branch
Galveston, TX
| | | Osteoarthritis | | | Optimal Use of Analgesics in the Management of Osteoarthritis Pain
Overview
Optimal Use of Analgesics in the Management of Osteoarthritis Pain will provide an evidence-based, guideline-based review of treatment options for managing osteoarthritis pain. Video-vignette, case-based learning will be used to illustrate education from expert presentations and guidelines. Special emphasis will be placed on physician-patient communication regarding pain management.
Objectives
Implement strategies for patient communication and education for management of OA pain and utilize pharmacologic and nonpharmacologic therapies for pain management according to guideline recommendations
Describe patient risk factors which could interact with various pain relief medications
Faculty
Frank LoVecchio, DO, MPH
Professor
Arizona College of Osteopathic Medicine
Midwestern University
Glendale, Arizona
Mark Fendrick, MD
Professor, Internal Medicine and Health Management & Policy Codirector, Center for Value-based Insurance Design
Coeditor in Cheif, American Journal of Managed Care
University of Michigan
Ann Arbor, Michigan
| | | ACS | | | Prevent The Event: Role of Oral Antiplatelet Therapy in the Management of the ACS Patient
Overview
The term acute coronary syndrome (ACS) is used to describe patients who present with either acute MI or unstable angina (UA). This program will provide an overview of ACS by discussing epidemiology, prevalance, acute and long term care treatment options as well as review current guidelines. Implementation of current treatment guidelines and patient adherence strategies in the primary care setting will also be discussed.
Objectives
Name 5 treatment recommendations for reduction of global CV risk in patients being medically managed for UA/NSTEMI
Describe 2 situations where dual antiplatelet therapy is recommended in patients with acute coronary syndrome
Faculty
Martin W. Schwarze, DO, FACC
Clinical Professor of Medicine
St. Louis University School of Medicine
St. Louis, MO
Lawrence E. Mieczkowski, MD
Clinical Associate Professor of Medicine
Wright State University School of Medicine
Medical Director, Center for Cardiometabolic Treatment
Dayton, OH
| | | Menstrual Migraine | | | A Practical Approach to Managing Menstrual Migraine: Tailoring Treatment and Individualizing Care
Overview
Migraine is a chronic, debilitating disorder that affects approximately 28 million Americans of whom ~18% are women and ~6% are men. When compared to migraines that occur during other times of the month, menstrual migraine (MM) may last longer and be more severe, disabling, frequent, and more difficult to treat. This program will address the new advances in the understanding of MM, the role of hormones, and how to select an appropriate treatment based on individual patient characteristics.
Objectives
Recognize migraine in the differential diagnosis of headaches that impact patients ability to fully function in their daily activities and identify menstrual migraine in female patients
Identify management strategies for women with menstrual migraine including use of headache calendars, behavioral modifications and approaches to acute and preventive treatment
Faculty
Susan L. Hutchinson, MD
Associate Clinical Professor, Department of Family Medicine
University of California, Irvine
Director, Orange County Migraine and Headache Center
Irvine, CA
Norman Gordon, MD
Chief of the Division of Neurology, Miriam Hospital
Clinical Associate Professor of Neurology, Brown University
Medical Director, CNS Research Inc.
Providence, RI
|
|
